SLC5A1

There are 52 papers on SLC5A1 in aging research: 5 trials and 4 observational studies in people, 22 in animals, 3 in cells, 16 reviews. The newest story, Nov 6, 2026: “Canagliflozin reduced calcium buildup in mouse arteries”.

Gene

52 papers study it3 findings

HGNCNCBI GeneTaxon

8 new papers in 30 daysSee all 52 papers on SLC5A1

At a glance

The findings reach mice, none yet in people. 2 independent labs in 2 countries; 43 trials, 9 with no results posted.

None of its findings points the other way.

Mice: a single group. Cells, worms or flies and humans: nothing yet.
  • 2 independent labs in 2 countries
  • 43 trials, 9 with no results posted
  • Funders: American Heart Association and 5 more
  • 42 of 43 trials sponsored by developers of drugs aimed at it
  • Human trial5
  • Humans4
  • Animals22
  • Cells3
  • In silico2

Interventions

1

Fasting

upin mice1

1 study
  1. Fasting activates SLC5A1 in mice.

    “fasting resulted in a selective increase in SGLT1 transport activity and Na+ selectivity at tight junctions in the jejunum, but not in the ileum.”

    Animalsjejunum24–48 hours

    The effect of fasting on sodium-dependent glucose absorption in the mouse proximal small intestine

    Research SquarePreprint

More on Fasting

Effects

2

Thrombus formation

upin mice1

1 study
  1. SLC5A1 increases thrombus formation in mice (Shown by platelet-specific Slc5a1 deletion in Slc5a1fl/fl Gp1ba-Cre+ mice).

    “a platelet-specific deletion of SGLT1 via Slc5a1fl/fl Gp1ba-Cre+ mice resulted in reduced platelet integrin activation and thrombus formation.”

    AnimalsShown by platelet-specific Slc5a1 deletion in Slc5a1fl/fl Gp1ba-Cre+ mice

    SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis

    The Journal of clinical investigation

Platelet integrin activation

upin mice1

1 study
  1. SLC5A1 increases platelet integrin activation in mice (Shown by platelet-specific Slc5a1 deletion in Slc5a1fl/fl Gp1ba-Cre+ mice).

    “a platelet-specific deletion of SGLT1 via Slc5a1fl/fl Gp1ba-Cre+ mice resulted in reduced platelet integrin activation and thrombus formation.”

    AnimalsShown by platelet-specific Slc5a1 deletion in Slc5a1fl/fl Gp1ba-Cre+ miceplatelet

    SGLT1/2 inhibitor sotagliflozin, but not SGLT2-selective inhibitor empagliflozin, attenuates platelet activation and thrombosis

    The Journal of clinical investigation

Latest

Dec 2025: 1Jan 2026: 5Feb 2026: 2Mar 2026: 7Apr 2026: 1May 2026: 1Jun 2026: 0Jul 2026: 0Aug 2026: 2Sep 2026: 2Oct 2026: 5Nov 2026: 430 papers in 12 months
bioRxiv

Canagliflozin reduced calcium buildup in mouse arteries

In experiments in mice fed a high-phosphate diet, canagliflozin reduced artery calcification while two related drugs did not.In experiments in mice fed a high-phosphate diet, canagliflozin reduced artery calcification while two related drugs did not.

Preprint: mouse studyCanagliflozin
ESC Congress 2026 Abstract

Sotagliflozin benefits held across blood pressure levels

In a randomized trial of 1,222 patients, benefits did not differ across starting systolic blood pressures of about 90 to 180 mmHg.In a randomized trial of 1,222 patients, benefits did not differ across starting systolic blood pressures of about 90 to 180 mmHg.

Randomized trial · 1,222 peopleSotagliflozin

See all 52 papers on SLC5A1